Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Limited / ARIAD Pharmaceuticals, Inc.

2017 · Acquisition/Merger · $5.2B · Complete

Announcement Sentiment

Positive

Takeda agreed to acquire ARIAD for $24.00/share in cash, an enterprise value of approximately $5.2B representing a ~75% premium. The deal expanded Takeda's oncology and hematology business with two targeted therapies: marketed Iclusig in CML and Phase 3 brigatinib in NSCLC. Acquisition completed February 16, 2017.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jan 09, 2017
Closed Feb 16, 2017
Deal value $5.2B
Deal type Acquisition/Merger
Therapeutic area Chronic myeloid leukemia (Iclusig); ALK-positive non-small cell lung cancer (brigatinib)
Indications Chronic myeloid leukemia (Iclusig); ALK-positive non-small cell lung cancer (brigatinib)
Key assets Iclusig (ponatinib); brigatinib
Mechanism BCR-ABL tyrosine kinase inhibitor (Iclusig); ALK inhibitor (brigatinib)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals